Goserelin ('Zoladex')-offering patients more choice in early breast cancer.
Authors
Mitchell, HelenAffiliation
Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. helen.mitchell@christie-tr.nwest.nhs.ukIssue Date
2004
Metadata
Show full item recordAbstract
The luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin alone, or in combination with tamoxifen, is at least as effective as cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy. Goserelin plus tamoxifen after cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy resulted in improved disease-free survival compared with CAF alone. These trials have also shown that goserelin is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of goserelin treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.Citation
Goserelin ('Zoladex')-offering patients more choice in early breast cancer. 2004, 8 Suppl 2:S95-103 Eur J Oncol NursJournal
European Journal of Oncology NursingDOI
10.1016/j.ejon.2004.09.004PubMed ID
15590321Type
ArticleLanguage
enISSN
1462-3889ae974a485f413a2113503eed53cd6c53
10.1016/j.ejon.2004.09.004
Scopus Count
Collections
Related articles
- Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
- Authors: International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD
- Issue date: 2003 Dec 17
- The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
- Authors: Robertson JF, Blamey RW
- Issue date: 2003 May
- Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
- Authors: Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study
- Issue date: 2002 Dec 15
- Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
- Authors: Kaufmann M
- Issue date: 1998 Sep
- Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
- Authors: Park IH, Ro J, Lee KS, Kim EA, Kwon Y, Nam BH, Jung SY, Lee S, Kim SW, Kang HS
- Issue date: 2010 Jun 1